CDKN2A and melanoma: When correlated with molecular data, MTAP loss showed 100% specificity and a positive predictive value of 100% for detecting CDKN2A homozygous deletion, but only 41% sensitivity, confirming that MTAP immunostaining alone lacks optimal sensitivity for detecting all CDKN2A-inactivated melanomas.